Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.56 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL31482341 | 0.97 | CA2 (0.54) | CA2ENPP2PLCG1AKR1C3PTGS2 | |
| SCHEMBL5908704 | 0.93 | CA2 (0.61) | CA2ENPP2PLCG1AKR1C3PTGS2 | |
| SCHEMBL10950514 | 0.87 | PTGS2 (0.54) | CA2ENPP2AKR1C3PTGS2CA9 | |
| SCHEMBL2376239 | 0.85 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL2156042 | 0.85 | AKR1C3 (0.59) | CA2ENPP2AKR1C3CA1FAAH | |
| SCHEMBL2157150 | 0.83 | ENPP2 (0.47) | CA2ENPP2PLCG1AKR1C3PTGS2 | |
| SCHEMBL30417605 | 0.82 | CA2 (0.50) | CA2PLCG1AKR1C3PTGS2CA12 | |
| SCHEMBL8974446 | 0.82 | PTGS2 (0.47) | CA2ENPP2AKR1C3PTGS2CA12 | |
| SCHEMBL11628318 | 0.80 | GSR (0.63) | AKR1C3MMP2MMP9MMP8FAAH | |
| SCHEMBL8651278 | 0.80 | PTGS2 (0.72) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1589 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823008-A | Preparation method of 4-methylsulfonyl phenylacetic acid | 浙江东亚药业股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-109678811-B | Asymmetric preparation method of florfenicol intermediate cyclic compound | 湖北中牧安达药业有限公司 | 2020-12-29 | — | — | CN | claimed |
| CN-108912020-A | Ao Dangka is replaced and its preparation method of intermediate | 上海博志研新药物技术有限公司 | 2018-11-30 | — | — | CN | claimed |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | claimed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | claimed |
| EP-0929519-B1 | BETA-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | UPJOHN CO (US) | 2005-02-23 | — | — | EP | claimed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | claimed |
| EP-0929519-A1 | $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-21 | — | — | EP | claimed |
| US-5847153-A | β-sulfonyl hydroxamic acids | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-08 | — | — | US | claimed |
| WO-1998013340-A1 | β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-02 | — | — | WO | claimed |
| CN-122070618-A | Graphite-based electrochemical cell | 铌博尔特有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026099505-A1 | SYSTEM FOR CONTROLLING BATTERY TEMPERATURE | NYOBOLT LIMITED (GB) | 2026-05-15 | — | — | WO | disclosed |
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4634118-B1 | NIOBIUM METAL OXIDE | NYOBOLT LTD (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20250382279-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-18 | — | — | US | disclosed |
| US-4801717-A | PLANT GROWTH REGULATORS | ROUSSEL UCLAF (FR) | 1989-01-31 | — | — | US | disclosed |
| US-4677214-A | Intermediates for preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols | SCHERING CORPORATION (US) | 1987-06-30 | — | — | US | disclosed |
| EP-0119892-B1 | HYDROXYL AMINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS GROWTH FACTORS FOR VEGETABLES AND COMPOSITIONS THEREOF | ROUSSEL-UCLAF (FR) | 1986-08-13 | — | — | EP | disclosed |
| US-4582918-A | Preparation of intermediates for (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols | SCHERING CORPORATION (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0119892-A1 | Hydroxyl amine derivatives, their preparation, their use as growth factors for vegetables and compositions thereof | ROUSSEL-UCLAF (FR) | 1984-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | CA2 4175/4885ENPP2 4473/4885PLCG1 3368/4885 |
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | APOL1, RNASE1, LOXL1 | CA2 3764/4885ENPP2 934/4885PLCG1 2036/4885 |
| US-20250382279-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, LATS1 | CA2 1779/4885ENPP2 3545/4885PLCG1 3932/4885 |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, RB1, ARG2 | CA2 4175/4885ENPP2 4473/4885PLCG1 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.